Sun Pharmaceutical Industries has entered into a deal to market Merck & Co's diabetes drugs - sitagliptin and sitagliptin plus metformin - in India, the two drugmakers said in a statement on Monday. Under the deal, Sun will have the rights to market the drugs only in India under different brand names, the firms said. Earlier in April, Sun and Merck formed a joint venture to develop and manufacture generic drugs for emerging markets.
This interview covers key results of the study ‘Success Factor Supply Chain Management and Logistics in the Chemical Industry 2024’ by Solventure, Aimms and Miebach.
Oxea is returning to its old name and its roots.
The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.
Jens Birgersson becomes new Brenntag CEO
Honeywell will acquire Johnson Matthey's Catalyst Technologies business segment for €2.15 billion in an all-cash transaction.
